Fludarabine/melphalan conditioning for allogeneic stem cell transplantation (SCT) in elderly patients with AML/MDS

被引：0
|
作者：
Kennedy, GA
Butler, J
Durrant, S
Hill, GR
Western, R
Morton, J
机构：
[1] Royal Brisbane & Womens Hosp, Div Oncol, Brisbane, Qld, Australia
[2] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5410
引用
收藏
页码：438B / 439B
页数：2
相关论文
共 50 条
  • [31] Dose-reduced conditioning with treosulfan/fludarabine followed by allogeneic stem cell transplantation from related and unrelated donors in patients with AML and MDS/sAML.
    Kroger, N
    Zabelina, T
    Schieder, H
    Ayuk, F
    Stute, N
    Kratochwille, A
    Fehse, N
    Hassenpflug, J
    Panse, J
    Casper, J
    Freund, M
    Zander, A
    BLOOD, 2003, 102 (11) : 334B - 334B
  • [32] BUSULFAN/CYCLOPHOSPHAMIDE VS. BUSULFAN/FLUDARABINE CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML/MDS: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
    Song, I.
    Ryu, H.
    Choi, Y.
    Lee, H.
    Yun, H.
    Kim, S.
    Jo, D.
    HAEMATOLOGICA, 2013, 98 : 656 - 657
  • [33] Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome
    Wais, V.
    Kuendgen, L.
    Bohl, S. R.
    von Harsdorf, S.
    Schlenk, R. F.
    Doehner, K.
    Teleanu, V.
    Bullinger, L.
    Nguyen, T. M.
    Drognitz, K.
    Moulin, J-C
    Binnenhei, M.
    Bentz, M.
    Doehner, H.
    Bunjes, D.
    Kuchenbauer, F.
    Ringhoffer, M.
    BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 94 - 96
  • [34] Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis
    Akanksha Chichra
    Lingaraj Nayak
    Rushabh Kothari
    Siddhesh Kalantri
    Avinash Bonda
    Anant Gokarn
    Sachin Punatar
    Sumeet Mirgh
    Nishant Jindal
    Bhausaheb Bagal
    Sadhana Kannan
    Libin Mathew
    Navin Khattry
    International Journal of Hematology, 2024, 119 : 71 - 79
  • [35] A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
    Andersson, Borje S.
    Thall, Peter F.
    Ma, Junsheng
    Valdez, Benigno C.
    Bassett, Roland, Jr.
    Chen, Julianne
    Ahmed, Sairah
    Alousi, Amin
    Bashir, Qaiser
    Ciurea, Stefan
    Gulbis, Alison
    Cool, Rita
    Kawedia, Jitesh
    Hosing, Chitra
    Kebriaei, Partow
    Kornblau, Steve
    Myers, Alan
    Oran, Betul
    Rezvani, Katayoun
    Shah, Nina
    Shpall, Elizabeth
    Parmar, Simrit
    Popat, Uday R.
    Nieto, Yago
    Champlin, Richard E.
    BONE MARROW TRANSPLANTATION, 2022, 57 (08) : 1295 - 1303
  • [36] Missing HLA C Group 1 Ligands in Patients with AML and MDS Is Associated with Reduced Risk of Relapse and Improved Survival after Allogeneic STEM CELL Transplantation (SCT) with Fludarabine and Treosulfan Reduced Toxicity Conditioning
    Shimoni, Avichai
    Bemardi, Massimo
    Yerushalmi, Ronit
    Peccatori, Iacopo
    Shem-Tov, Noga
    Lo Russo, Alessandro
    Volchek, Yulia
    Bonini, Maria Chiara
    Nagler, Arnon
    Ciceri, Fabio
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S280 - S281
  • [37] Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome
    V Wais
    L Kündgen
    S R Bohl
    S von Harsdorf
    R F Schlenk
    K Döhner
    V Teleanu
    L Bullinger
    T M Nguyen
    K Drognitz
    J-C Moulin
    M Binnenhei
    M Bentz
    H Döhner
    D Bunjes
    F Kuchenbauer
    M Ringhoffer
    Bone Marrow Transplantation, 2018, 53 : 94 - 96
  • [38] A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
    Borje S. Andersson
    Peter F. Thall
    Junsheng Ma
    Benigno C. Valdez
    Roland Bassett
    Julianne Chen
    Sairah Ahmed
    Amin Alousi
    Qaiser Bashir
    Stefan Ciurea
    Alison Gulbis
    Rita Cool
    Jitesh Kawedia
    Chitra Hosing
    Partow Kebriaei
    Steve Kornblau
    Alan Myers
    Betul Oran
    Katayoun Rezvani
    Nina Shah
    Elizabeth Shpall
    Simrit Parmar
    Uday R. Popat
    Yago Nieto
    Richard E. Champlin
    Bone Marrow Transplantation, 2022, 57 : 1295 - 1303
  • [39] Conditioning with treosulfan and fludarabine for allogeneic blood stem cell transplantation
    Casper, J
    Steiner, B
    Wolff, D
    Kleine, HD
    Wilhelm, S
    Hammer, U
    von Wurmb, N
    Roeber, S
    Wegener, R
    Freund, M
    BONE MARROW TRANSPLANTATION, 2001, 27 : S285 - S286
  • [40] Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis
    Yamamoto, Wataru
    Andou, Taiki
    Itabashi, Megumi
    Koyama, Satoshi
    Ishii, Yoshimi
    Numata, Ayumi
    Motohashi, Kenji
    Hagihara, Maki
    Matsumoto, Kenji
    Fujisawa, Shin
    INTERNAL MEDICINE, 2016, 55 (13) : 1721 - 1727
12345